Transplant ID

An investigational T-cell therapy shows promise against six viral infections common after stem cell transplants

13 Jan, 2023 | 13:10h | UTC

News Release: An investigational T-cell therapy shows promise against six viral infections common after stem cell transplants – American Association for Cancer Research

Original Article: Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting – Clinical Cancer Research

Commentary: Study Finds Posoleucel Demonstrated Antiviral Efficacy and Safety Against Viral Infections Following Allogeneic Stem Cell Transplantation – The ASCO Post

 

---

RCT: Maribavir for refractory Cytomegalovirus infections with or without resistance post-transplant.

7 Dec, 2021 | 08:37h | UTC

Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results from a Phase 3 Randomized Clinical Trial – Clinical Infectious Diseases

 

---

Study Commentary: Febrile Neutropenia – Procalcitonin vs. MASCC Score.

8 Jul, 2021 | 08:57h | UTC

Febrile Neutropenia – Procalcitonin vs MASCC Score – Journal Feed

Original study: Prognostic Value of Serum Procalcitonin Levels in Patients With Febrile Neutropenia Presenting to the Emergency Department – The Journal of Emergency Medicine

 

---

Review: Long-Term Infectious Complications of Kidney Transplantation

22 Apr, 2021 | 08:16h | UTC

Long-Term Infectious Complications of Kidney Transplantation – Clinical Journal of the American Society of Nephrology

 

---

[Abstract Only] Randomized trial: Antibiotics vs. no therapy in kidney transplant recipients with asymptomatic bacteriuria

11 Sep, 2020 | 01:10h | UTC

Antibiotics versus no therapy in kidney transplant recipients with asymptomatic bacteriuria (BiRT): a pragmatic, multicentre, randomised controlled trial – Clinical Microbiology and Infection

 

Commentary on Twitter

More data ❌ screening/Rxing asymptomatic bacteriuria in kidney transplantation

199 KTx recipients (>2 mo out) randomized to Rx/no Rx for ASB

Rx arm had
💊No ⬇️ in symptomatic UTI
💊5x more ABx exposure
💊subsequent bacteriuria w resistant bacteria #TxIDhttps://t.co/a7aVjIJj0z pic.twitter.com/ngTkJLHCfU

— Ilan Schwartz MD PhD (@GermHunterMD) September 10, 2020

 

---